The analysis of sequences in the 5ʹ upstream region of STC2, a gene known to promote prostate cancer proliferation, revealed that the combination treatment induced at least a slight increase in DNA methylation (40%) compared with the controls (35%) (Figure 5A). This evidence concerns the gene STC2 and prostate carcinoma.